Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 3/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 3/20 | 0.32 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL10775461 | 0.91 | FFAR3 (0.39) | FFAR3LCKFYNALDH1A1TSHR | |
| Cyclohexane SCHEMBL28420503 | 0.91 | FFAR3 (0.40) | FFAR3LCKFYNALDH1A1TSHR | |
| Acetic Acid SCHEMBL31254063 | 0.84 | FFAR3 (0.44) | FFAR3LCKFYNALDH1A1TSHR | |
| Methacrylic Acid SCHEMBL28927409 | 0.83 | TDP1 (0.35) | FFAR3LCKFYNALDH1A1TSHR | |
| Acetic Acid SCHEMBL10866598 | 0.80 | FFAR3 (0.47) | FFAR3LCKFYNALDH1A1TSHR | |
| Trichlorethanol SCHEMBL2141590 | 0.80 | FFAR3 (0.47) | FFAR3LCKFYNALDH1A1TSHR | |
| Acetic Acid SCHEMBL10593009 | 0.79 | FFAR3 (0.39) | FFAR3LCKFYNALDH1A1TSHR | |
| Carbon Tetrachloride SCHEMBL3963583 | 0.78 | — | — | |
| SCHEMBL22731 | 0.78 | — | — | |
| Trichlorethanol SCHEMBL8976783 | 0.78 | FFAR3 (0.44) | FFAR3LCKFYNALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022071226-A1 | RESIN COMPOSITION, CURED PRODUCT, LAMINATE, CURED PRODUCT PRODUCTION METHOD, AND SEMICONDUCTOR DEVICE | 富士フイルム株式会社 | 2022-04-07 | — | — | WO | disclosed |
| CN-108218949-B | Preparation method of 3, 29-dibenzoyl trichosanthes kirilowii kernel triol reference substance | 上海诗丹德标准技术服务有限公司 | 2020-12-18 | — | — | CN | disclosed |
| US-7348433-B2 | Quinolinones as prostaglandin receptor ligands | MERCK FROSST CANADA & CO. (CA) | 2008-03-25 | — | — | US | disclosed |
| EP-1458718-B1 | QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA LTD (CA) | 2006-10-25 | — | — | EP | disclosed |
| US-20050222194-A1 | Quinolinones as prostaglandin receptor ligands | MERCK FROSST CANADA LTD. (CA) | 2005-10-06 | — | — | US | disclosed |
| EP-1458718-A1 | QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS | Merck Frosst Canada & Co. (CA) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003051878-A1 | QUINOLINONES AS PROSTAGLANDIN RECEPTOR LIGANDS | MERCK FROSST CANADA & CO. (CA) | 2003-06-26 | — | — | WO | disclosed |
| US-5591862-A | ANTILIPEMICS, TREATING DIABETES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-01-07 | — | — | US | disclosed |
| EP-0451538-B1 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-05-22 | — | — | EP | disclosed |
| EP-0361317-B1 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-04-05 | — | — | EP | disclosed |
| US-5290785-A | Therapeutic agent for ischemic diseases | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-01 | — | — | US | disclosed |
| US-5173493-A | For treatment or prevention of nausea or vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-12-22 | — | — | US | disclosed |
| US-5141945-A | 5-Hydroxytryptamine antagonists, treatment or prevention of nausea and vomiting | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-08-25 | — | — | US | disclosed |
| EP-0451538-A2 | Use of pyridoindole derivatives in the treatment of ischemic disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-10-16 | — | — | EP | disclosed |
| EP-0361317-A2 | Pyridoindole derivatives and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222194-A1 | Quinolinones as prostaglandin receptor ligands | PTGFR, PTGER1, PTGER2 | FFAR3 162/4885LCK 1682/4885FYN 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.